Multivariable analysis of the association between RA treatments and risk of B-cell NHL or Hodgkin’s lymphoma, adjusting for sex, autoantibodies, erosions and DAS28
| OR (95% CI) | |
| Hydroxychloroquine | 3.48 (0.69 to 19.19) |
| Sulfasalazine | 1.32 (0.26 to 6.49) |
| Male sex | 3.13 (1.00 to 10.56) |
| RF or ACPA positivity | 1.67 (0.39 to 9,10) |
| Erosion on radiographs at the time of matching | 9.87 (3.51 to 31.49) |
| DAS28 at the time of matching | 2.09 (1.41 to 3.38) |
ACPA, anti-citrullinated peptide antibodies; DAS28, disease activity score in 28 joints; NHL, non-Hodgkin's lymphoma; RA, rheumatoid arthritis; RF, rheumatoid factor.